Structural basis for suppression of hypernegative DNA supercoiling by E. coli topoisomerase I

Escherichia coli topoisomerase I has an essential function in preventing hypernegative supercoiling of DNA. A full length structure of E. coli topoisomerase I reported here shows how the C-terminal domains bind single-stranded DNA (ssDNA) to recognize the accumulation of negative supercoils in duplex DNA. These C-terminal domains of E. coli topoisomerase I are known to interact with RNA polymerase, and two flexible linkers within the C-terminal domains may assist in the movement of the ssDNA for the rapid removal of transcription driven negative supercoils. The structure has also unveiled for the first time how the 4-Cys zinc ribbon domain and zinc ribbon-like domain bind ssDNA with primarily π-stacking interactions. This novel structure, in combination with new biochemical data, provides important insights into the mechanism of genome regulation by type IA topoisomerases that is essential for life, as well as the structures of homologous type IA TOP3α and TOP3β from higher eukaryotes that also have multiple 4-Cys zinc ribbon domains required for their physiological functions

Regulation of lipid biosynthesis, sliding motility, and biofilm formation by a membrane-anchored nucleoid-associated protein of Mycobacterium tuberculosis

Bacteria use a number of small basic proteins for organization and compaction of their genomes. By their interaction with DNA, these nucleoid-associated proteins (NAPs) also influence gene expression. Rv3852, a NAP of Mycobacterium tuberculosis, is conserved among the pathogenic and slow-growing species of mycobacteria. Here, we show that the protein predominantly localizes in the cell membrane and that the carboxy-terminal region with the propensity to form a transmembrane helix is necessary for its membrane localization. The protein is involved in genome organization, and its ectopic expression in Mycobacterium smegmatis resulted in altered nucleoid morphology, defects in biofilm formation, sliding motility, and change in apolar lipid profile. We demonstrate its crucial role in regulating the expression of KasA, KasB, and GroEL1 proteins, which are in turn involved in controlling the surface phenotypes in mycobacteria

Wake Me When It\u27s Over- Bacterial Toxin-Antitoxin Proteins and Induced Dormancy

Toxin-antitoxin systems are encoded by bacteria and archaea to enable an immediate response to environmental stresses, including antibiotics and the host immune response. During normal conditions, the antitoxin components prevent toxins from interfering with metabolism and arresting growth; however, toxin activation enables microbes to remain dormant through unfavorable conditions that might continue over millions of years. Intense investigations have revealed a multitude of mechanisms for both regulation and activation of toxin-antitoxin systems, which are abundant in pathogenic microorganisms. This minireview provides an overview of the current knowledge regarding type II toxin-antitoxin systems along with their clinical and environmental implications

Keeping the Wolves at Bay: Antitoxins of Prokaryotic Type II Toxin-Antitoxin Systems

In their initial stages of discovery, prokaryotic toxin-antitoxin (TA) systems were confined to bacterial plasmids where they function to mediate the maintenance and stability of usually low- to medium-copy number plasmids through the post-segregational killing of any plasmid-free daughter cells that developed. Their eventual discovery as nearly ubiquitous and repetitive elements in bacterial chromosomes led to a wealth of knowledge and scientific debate as to their diversity and functionality in the prokaryotic lifestyle. Currently categorized into six different types designated types I–VI, type II TA systems are the best characterized. These generally comprised of two genes encoding a proteic toxin and its corresponding proteic antitoxin, respectively. Under normal growth conditions, the stable toxin is prevented from exerting its lethal effect through tight binding with the less stable antitoxin partner, forming a non-lethal TA protein complex. Besides binding with its cognate toxin, the antitoxin also plays a role in regulating the expression of the type II TA operon by binding to the operator site, thereby repressing transcription from the TA promoter. In most cases, full repression is observed in the presence of the TA complex as binding of the toxin enhances the DNA binding capability of the antitoxin. TA systems have been implicated in a gamut of prokaryotic cellular functions such as being mediators of programmed cell death as well as persistence or dormancy, biofilm formation, as defensive weapons against bacteriophage infections and as virulence factors in pathogenic bacteria. It is thus apparent that these antitoxins, as DNA-binding proteins, play an essential role in modulating the prokaryotic lifestyle whilst at the same time preventing the lethal action of the toxins under normal growth conditions, i.e., keeping the proverbial wolves at bay. In this review, we will cover the diversity and characteristics of various type II TA antitoxins. We shall also look into some interesting deviations from the canonical type II TA systems such as tripartite TA systems where the regulatory role is played by a third party protein and not the antitoxin, and a unique TA system encoding a single protein with both toxin as well as antitoxin domains.Work supported by Grants CSD2008/00013 (to ME and WTC), and BIO2015-69085-REDC and BIO2013-49148-C2-2-R (to ME) from the Spanish Ministry of Economy and Competitiveness; PRPUM grant CG011-2014 (to CCY) from the Malaysian Ministry of Higher Education.Peer reviewedPeer Reviewe

Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

Drug-recalcitrant infections are a leading global-health concern. Bacterial cells benefit from phenotypic variation, which can suggest effective antimicrobial strategies. However, probing phenotypic variation entails spatiotemporal analysis of individual cells that is technically challenging, and hard to integrate into drug discovery. In this work, we develop a multi-condition microfluidic platform suitable for imaging two-dimensional growth of bacterial cells during transitions between separate environmental conditions. With this platform, we implement a dynamic single-cell screening for pheno-tuning compounds, which induce a phenotypic change and decrease cell-to-cell variation, aiming to undermine the entire bacterial population and make it more vulnerable to other drugs. We apply this strategy to mycobacteria, as tuberculosis poses a major public-health threat. Our lead compound impairs Mycobacterium tuberculosis via a peculiar mode of action and enhances other anti-tubercular drugs. This work proves that harnessing phenotypic variation represents a successful approach to tackle pathogens that are increasingly difficult to treat.</br

The genetic background modulates the evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis

Fluoroquinolones (FQ) form the backbone in experimental treatment regimens against drug-susceptible tuberculosis. However, little is known on whether the genetic variation present in natural populations of Mycobacterium tuberculosis (Mtb) affects the evolution of FQ-resistance (FQ-R). To investigate this question, we used nine genetically distinct drug-susceptible clinical isolates of Mtb and measured their frequency of resistance to the FQ ofloxacin (OFX) in vitro. We found that the Mtb genetic background led to differences in the frequency of OFX-resistance (OFX-R) that spanned two orders of magnitude and substantially modulated the observed mutational profiles for OFX-R. Further, in vitro assays showed that the genetic background also influenced the minimum inhibitory concentration and the fitness effect conferred by a given OFX-R mutation. To test the clinical relevance of our in vitro work, we surveyed the mutational profile for FQ-R in publicly available genomic sequences from clinical Mtb isolates, and found substantial Mtb lineage-dependent variability. Comparison of the clinical and the in vitro mutational profiles for FQ-R showed that 51% and 39% of the variability in the clinical frequency of FQ-R gyrA mutation events in Lineage 2 and Lineage 4 strains, respectively, can be attributed to how Mtb evolves FQ-R in vitro. As the Mtb genetic background strongly influenced the evolution of FQ-R in vitro, we conclude that the genetic background of Mtb also impacts the evolution of FQ-R in the clinic

Mutagenic effect of antibiotics on Escherichia coli and new genes of antibiotic resistance in Mycobacterium smegmatis

Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. Fecha de lectura: 19-03-201

Identification and comparison of protein composition of biofilms in response to EGCG from Enterococcus faecalis and Staphylococcus lugdunensis, which showed opposite patterns in biofilm-forming abilities

Bacterial biofilm is resistant to conventional antibiotic treatments, leading to complications associated with many infection-related human diseases. Epigallocatechin Gallate (EGCG), a phenolic catechin enriched in green tea, is recognized for its anti-bacterial and anti-biofilm activities. In this study, we examined the protein components of the biofilms formed in the absence or presence of EGCG using Enterococcus faecalis and Staphylococcus lugdunensis, which had shown opposing patterns in biofilm formation. A clustering heatmap revealed that the two microorganisms expressed the different protein sets in response to EGCG. Proteins that were noticeably upregulated included those associated with stress responsiveness and gluconeogenesis in E. faecalis, and gene modification in S. lugdunensis. Conversely, downregulated proteins were related to tRNA-modifying enzyme activity in E. faecalis, and anabolic metabolism in S. lugdunensis. Among the proteins identified only in EGCG-responsive biofilms, enzymes involved in de novo purine biosynthesis were enriched in E. faecalis, while proteins likely to cause DNA instability and pathogenicity changes were abundantly present in S. lugdunensis. The classification based on gene ontology (GO) terms by microorganism exhibited that metabolic process or catabolic activity was at the top rank in E. faecalis with more than 33 proteins, and in S. lugdunensis, localization or transport was highly ranked with 4 proteins. These results support the hypothesis that EGCG might cause different cellular programs in each microorganism. Finally, comparison of the proteomes between two groups that form biofilms to similar extents discovered that 2 proteins were commonly found in the weak biofilm-forming groups (E. faecalis and EGCG-responding S. lugudunensis), whereas 9 proteins were common among the strong biofilm-forming groups (S. lugdunensis and EGCG-responding E. faecalis). It was suggested that these proteins could serve as potential indicators to detect the presence and predict the extent of biofilm formation by multiple microorganisms. Taken all together, proteomics data and analyses performed in this study provided useful and new information on the proteins embedded in the biofilms formed at the specific conditions, which can aid in diagnosis and the development of tailored treatment strategies. © 2024 The AuthorsTRUEscopu

Comprehensive characterization of Mycobacterium tuberculosis strains after acquisition of isoniazid resistance

Includes bibliographical references.2016 Fall.Despite the global efforts to reduce tuberculosis (TB) rates, the emergence of drug resistant TB has not allowed effective control of this disease. In the last decade, there were roughly 10 million new TB cases per year and isoniazid resistant (INHr) TB accounted for 9.5% of these cases around the world. In 2012, United States had an interruption in the supply of isoniazid (INH), which increased the likelihood of INH resistance rates. Although INH resistance in Mycobacterium tuberculosis (Mtb) is multigenic, mutations in the catalase-peroxidase (katG) gene predominate amongst INHr Mtb strains. The characterization of the Mtb proteome before and after acquiring INH resistance remains understudied. Additionally, the effect of these drug-resistance-conferring mutations on Mtb fitness and virulence is variable. The purpose of this work is to describe a complete biochemical and immunological characterization of the INHr acquisition in Mtb. In this way, a global exploration of the protein and mycolic acids differences in Mtb cultures, as well as differences in the immune response and bacterial virulence in the mouse model comparing clonal susceptible and INHr pairs of Mtb were evaluated. After this, common trends were analyzed and the findings were interpreted in the context of bacterial metabolism and host-interaction. For this work, two clonal clinical Mtb strains and one laboratory clonal pair of the H37Rv strain with different susceptibility profiles to INH were studied. The H37Rv INHr strain was isolated from a mouse that was exposed to INH in the lab and developed the same katG mutation that one of the clinical INHr strain has (V1A). In all cases, the first strain was susceptible to all tested drugs (mostly known as the INHs strain in this dissertation) while the second strain was resistant only to INH (named INHr throughout this work). The clinical pairs were confirmed as clonal pairs of the Beijing and T genotype respectively by spoligotyping and restriction fragment polymorphism analysis that uses the patterns given by the distribution of the insertion sequence (IS)-6110. Previous whole genome sequencing analysis of the clinical clonal pairs showed a katG mutation and the presence of some additional non-synonymous polymorphisms in the INHr strains. After the proteomic analysis, a katG PCR sequencing confirmed two mutations in katG for the T INHr pair (V1A and E3V) while the L101R mutation previously identified for the Beijing INHr was not confirmed. This mutation was highly unstable and the Beijing INHr might have reversed its phenotype after the absence of INH during in vitro growth. Therefore, the analysis with the Beijing clonal pair is only presented in chapter II. Protein comparison of secreted and cellular fractions (membrane, cytosol and cell wall) between clinical and lab clonal pairs of Mtb before and after acquisition of INH resistance revealed at least 25 commonly altered proteins looking at the same cellular fractions. These proteins were involved in ATP synthase machinery, lipid metabolism, regulatory events, virulence, detoxification and adaptation processes. Western blot analysis supported some of our findings, particularly the lower level of bacterial enzyme KatG in the INHr strains. Mycolic acid (MA) analysis in these clonal pairs did not reveal a common trend in these molecules for INHr strains but generated supporting information about an alternative fatty acid biosynthetic pathway in the clinical INHr strain. These analyses are further described in chapter III. Additionally, differences in bacterial growth, immune response and pathology induced by Mtb strains harboring mutations at the N-terminus of KatG were evaluated in the C57BL/6 mouse model. The results in the mouse study support the idea of the individual effect of specific located mutations in the katG gene together with the associated changes in the bacterial proteome induce differences in the Mtb virulence and pathogenicity. In addition, the in vivo results also suggest the contribution of innate immune response via TLR-2 in the clearance of the INHr-attenuated Mtb strains. Further details of this work are described in chapter IV. This work provides a better understanding of new compensatory mechanisms in Mtb after INH resistance acquisition providing novel information that could be used to address alternative combined therapies as well as the identification of new drug targets in INHr strains. The results presented here also contribute to the generation of new hypothesis regarding RNA decay in Mtb and the need to evaluate if the observed biochemical differences are also associated with the bacterial exposure to the first line drug therapy that occurred in the patient. After the results obtained in this study, a subsequent biochemical analysis of Mtb strains obtained from patients before and after drug treatment is proposed to improve the description of the evolution of the acquired drug resistant phenomena observed in TB cases that limit the global disease control and hence its eradication (chapter V)